Table 3 Incidence trends of myeloid neoplasms diagnosed during 2002–2013 in Spain.

MPN

5872

1.6 (0.8; 2.4)

*

Chronic myeloid leukemia

1324

 − 2.1 (− 3.7; − 0.4)

*

Polycythemia vera

1064

2.2 (0.3; 4.1)

*

Primary myelofibrosis

457

3.5 (0.6; 6.5)

*

Essential thrombocythemia

2401

4.6 (3.3; 5.9)

*

Chronic neutrophilic/eosinophilic leukemia

53

 − 1.1 (− 9.0; 7.5)

Mastocytosis

83

0.6 (− 5.9; 7.5)

MPN unclassifiable

490

 − 5.0 (− 7.6; − 2.4)

*

MDS/MPN

912

6.9 (4.8; 9.1)

*

Chronic myelomonocytic leukemia

763

5.3 (3.0; 7.6)

*

Juvenile myelomonocytic leukemia

8

–

Atypical chronic myeloid leukemia

49

10.1 (0.8; 20.4)

*

MDS/MPN, unclassifiable

92

19.7 (11.6; 28.1)

*

MDS

5213

1.3 (0.4; 2.1)

*

MDS with single lineage dysplasia

731

 − 11.9 (− 13.9; − 9.8)

*

MDS with ring sideroblasts and single lineage dysplasia

471

 − 2.5 (− 5.2; 0.3)

MDS with excess of blasts

912

0.8 (− 1.2; 2.8)

MDS with multilineage dysplasia

782

19.1 (16.3; 21.9)

*

MDS associated with isolated del(5q)

116

13.7 (7.2; 20.6)

*

MDS unclassifiable

2201

0.8 (− 0.5; 2.1)

AML

4498

0.8 (− 0.5; 2.1)

AML with recurrent cytogenetic abnormalities

608

4.2 (1.6; 6.7)

*

AML with multilineage dysplasia

494

4.6 (1.8; 7.5)

*

AML and MDS therapy related

120

22.3 (15.0; 30.0)

*

AML NOC

2136

1.4 (0.1; 2.8)

*

AML NOS

1140

 − 5.2 (− 6.9; − 3.4)

*

Acute leukemia of ambiguous lineage

395

 − 9.2 (− 12.0; − 6.3)

*

Unknown myeloid neoplasms

632

 − 14.3 (− 16.5; − 12.1)

*

Total cases

17,522

0.7 (0.3; 1.2)

*